Ultra-Low-Power Medical Sensor PCBA for Multi-Parameter Wearables

On September 3, 2026, the digital health industry continued to follow the FDA authorization of Abbott Libre Duo 10 Day. The FDA granted authorization on August 25 through the De Novo pathway for a continuous glucose and ketone monitoring system indicated for people with diabetes aged two and older, capable of monitoring both parameters continuously over a wear period of up to ten days. It is the first wearable device in the United States authorized to monitor ketones continuously, and the first in the world to track both parameters in a single device. The FDA disclosed that the clinical program covered six studies and more than 600 participants.

For electronics manufacturing, the interesting question is not what the device measures. It is what adding a second measurement channel does to the hardware, and how that complexity propagates down to the board and assembly process.

Adding a Parameter Does Not Double the Difficulty

Continuous glucose monitoring has settled into a relatively mature hardware architecture over the past decade. Adding ketone monitoring is not simply a matter of adding one more sensor to an existing design.

Glucose and ketones are different biochemical signals requiring different detection channels. Both channels must operate simultaneously inside a skin-mounted device where size and power are tightly constrained, while avoiding interference from the analog front end, the power supply and the wireless communication subsystem. Abbott states that the system measures both glucose and ketones once per minute and integrates the data into a single digital health platform.

For the hardware, sampling frequency is not the hardest part. Maintaining consistency of very weak biochemical signals over a ten day wear period is. If the analog front end is affected by power supply ripple, radio frequency noise or crosstalk between channels, the result appears as measurement drift, which is indistinguishable from a physiological change and is therefore a clinical problem rather than a technical one.

The core requirement on the PCB therefore shifts from making components small to isolating signals of different natures within an extremely small volume. That is a layout and stackup problem as much as a component selection problem.

HDI and Flex Take On More of the System

A skin-mounted medical device must satisfy volume, weight, wearing comfort and battery life requirements simultaneously, which leaves very little space for electronics. The main controller, analog front end, power management, wireless communication and sensor interface all have to compress further, and ordinary multilayer boards increasingly cannot resolve the routing problem by growing in area.

This is where HDI becomes valuable. Smaller laser microvias and higher routing density shorten the distance between critical analog traces and their associated components, while leaving more continuous space for power and ground networks. Keeping the analog front end physically close to the sensor interface reduces both noise pickup and parasitic effects, which directly supports measurement stability.

Where the product includes irregular connections between the sensor, the battery and the main controller, flexible circuits can conform to the enclosure and reduce the space consumed by connectors and conventional wiring harnesses. Combining HDI main boards with flex interconnects is now a common architecture for wearables, and it is increasingly the default approach for multi-parameter devices.

What increases manufacturing difficulty is tolerance at reduced scale. Small pads, fine traces and high density BGA packages are more sensitive to imaging quality, laser drilling accuracy, layer-to-layer registration and SMT placement precision. A design can be routed densely on paper, but building it repeatedly and consistently is a separate question that depends on PCB design and layout decisions made with process capability in mind.

Ten Days of Wear Pushes Power Into the Board

The maximum wear period for the Libre Duo is ten days. In a space constrained wearable, enlarging the battery is generally not an option, so battery life has to come from reducing consumption across sensing, computation, communication and power management together.

That makes leakage, parasitic parameters and power integrity on the board far more consequential. For analog circuitry detecting weak electrochemical signals, surface contamination, flux residue or a localized change in insulation resistance can all affect long term operating stability. A leakage path that would be irrelevant on a consumer device drawing milliamps can shift a microamp level measurement enough to matter.

At the PCBA stage, solder paste printing, reflow profile, cleaning and joint consistency stop being questions about whether the product powers on. They become questions about whether it can collect reliable data across a continuous wear period. Residue left under a component or an incomplete cleaning step may not cause a functional failure at final test, but it can alter behavior weeks later or across a temperature range that only occurs during actual wear.

This is the essential difference between medical wearables and ordinary consumer electronics. The former requires not just small size but sustained consistency at small size, and consistency must hold in production volume rather than only in engineering samples.

Assembly Quality Becomes Part of the Measurement Chain

Once a device monitors multiple biochemical parameters, the assembled board is part of the measurement instrument. Solder joint quality, cleanliness and dimensional consistency influence signal integrity in ways that are difficult to separate from sensor behavior after the fact.

Process control therefore has to be structured to detect problems before they are embedded. Solder paste inspection verifies deposition volume, which determines joint formation. Automated optical inspection catches placement and soldering defects on visible joints. X-ray inspection reveals voids and incomplete joints beneath BGA packages, which is especially relevant where a device dissipates little heat and therefore cannot rely on reflow to correct marginal joints during operation. Electrical and functional testing confirms that the assembled unit behaves within specification.

Each of these steps produces a record. Taken together, they form the evidence base for quality management claims, and for medical devices that evidence is not optional. When a production question arises months later, the ability to trace a specific unit back to a paste lot, a reflow profile and an inspection result is what makes resolution possible.

Where a program is still in development and needs to validate several design iterations quickly, rapid PCBA prototyping supports the iteration cycle without sacrificing the measurement discipline. The value of fast builds is highest when each build produces comparable data, because that is what allows a design change to be evaluated against a stable baseline rather than against a moving one.

Regulation Raises the Bar on Consistency

The FDA also established a new iCGK category for continuous glucose and ketone monitoring along with corresponding special controls. That matters to the hardware supply chain because once multi-parameter monitoring enters a formal regulatory framework, attention extends beyond whether a prototype can be built to include batch consistency, process traceability and test capability.

For PCB and PCBA manufacturers, high order HDI, flexible circuits and high density SMT assembly are baseline capabilities rather than differentiators. What determines whether a medical program can sustain volume production is whether fine line imaging, microvia formation and solder joint quality remain stable over time, and whether inspection and test steps combine into a closed quality loop.

Multi-parameter medical wearables also benefit from keeping fabrication and assembly within one manufacturing chain. When medical PCBA assembly and flex PCB assembly are handled alongside board fabrication under a shared process discipline, a shift detected at functional test can be traced back to the material, drilling or assembly step that produced it, rather than being attributed to sensor variability that cannot be investigated.

Materials and Coating for Skin-Contacted Hardware

Wearable medical devices introduce a materials dimension that ordinary consumer electronics do not face, because the enclosure and the board behind it sit against the skin for days at a time.

Biocompatibility requirements under ISO 10993 place constraints on materials that come into contact with the wearer, and those constraints propagate into coating and encapsulation choices on the assembly. A conformal coating selected for moisture protection on an industrial board may not be appropriate here, and the decision has to be made with the regulatory pathway in mind rather than added at the end.

Coating coverage also interacts directly with measurement stability. High impedance sensing nodes need protection from surface contamination and humidity induced leakage, which argues for thorough coverage. Test points and connector interfaces need to remain accessible, which argues for selective coverage. Resolving that tension requires defining which nodes are electrically critical before the assembly drawing is finalized, because reworking a coating decision after a clinical build is expensive.

Cleaning is the other side of the same problem. Flux residue left beneath a component creates both a leakage path and a long term corrosion risk, and on a device with microamp level analog signals the resulting drift can be mistaken for a physiological change. Specifying ionic cleanliness limits and verifying them through extraction testing converts cleaning from a process assumption into a measured property.

Encapsulation and coating also affect the mechanical behavior of the assembly. A coating that is stiffer than the substrate can crack at flex transitions, which is a particular risk where a flexible interconnect meets a rigid section. Reviewing coating selection together with mechanical flexing rather than separately prevents a failure mode that only appears after repeated movement during wear.

What the Next Generation Looks Like

The more significant signal in the Libre Duo authorization is not that wearables gained another medical function. It is that as sensor count rises, system complexity is propagating rapidly into board level manufacturing.

If glucose, ketones, lactate and additional biomarkers continue to be integrated into the same device, the PCB value in medical wearables will not come primarily from increased board area. It will concentrate in miniature HDI structures, flexible interconnect, precise analog signal handling and high reliability assembly capable of maintaining long term stability within a very small space.

For engineering teams, the practical implication is that the manufacturing partner should be involved while the analog architecture is still being defined. Decisions about grounding, partitioning, material selection and coating coverage determine measurement stability, and those decisions are far cheaper to change during layout review than after a clinical validation program has been completed.